Company intelligence / Profile preview

Neuvotion

Stamford, Connecticut, United Statesneuvotion-inc.com ↗

Ownership: Private
Development stage: Commercial

Overview

Neuvotion has received FDA clearance for its first product, NeuStim™, a non-invasive wearable device that delivers high-resolution electrical stimulation to support hand movement recovery after stroke or spinal cord injury. Clinical studies are ongoing/multi-site trials planned. The company’s approach combines targeted neurostimulation with artificial intelligence to accelerate and improve rehabilitation outcomes.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (neurostimulation)AI-driven neuromodulation technology
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

NeuStim

Commercial

Indications: Stroke, Spinal cord injury

Partnerships

Intelligent Product Solutions / Forward Industries (engineering/design/manufacturing partner/investor)Good Shepherd Rehabilitation Network (clinical research partner/test site)

Beyond the preview

Go deeper on Neuvotion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuvotion.

Explore the full profile